• Education

    University of Bern, 1989

  • Residencies

    Indiana University School of Medicine, Internal Medicine, 1996

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, Hematology-Oncology, 2000

  • Academic Title

    Professor

  • Languages

    French

    German

    Italian

Clinics I work with

Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

Hereditary Cancer Clinic

Bakar Precision Cancer Medicine Building

See both of our San Francisco locations.

My reviews

4.7

Overall Experience
108 Reviews
I count myself among the luckiest people on earth to have a caregiver such as Dr Munster. She is brilliant a top professional and a warm and compassionate human being. They don't make them like her anymore.
Explained things in a way that was easy to understand
108 Reviews
Did the doctor pay attention to your concerns
108 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
103 Reviews
Knew the important information about your medical history
106 Reviews
The provider showed respect for what you had to say
107 Reviews
The provider spent enough time with me
107 Reviews
Decorative Caduceus

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.

Recruiting

Decorative Caduceus

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy

Recruiting

Decorative Caduceus

AO-176 in Multiple Solid Tumor Malignancies

Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.

Recruiting

Decorative Caduceus

9-ING-41 in Patients With Advanced Cancers

The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.

Recruiting

Decorative Caduceus

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or M...

Recruiting

Decorative Caduceus

Study of ORIC-101 in Combination With Anticancer Therapy

RP2D as determined by 3+3 dose escalation design

Recruiting

Decorative Caduceus

A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in H...

Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in patients with advanced prostate cancer).

Recruiting

Decorative Caduceus

Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and R...

Incidence, nature, and severity of treatment-emergent AEs and SAEs, graded according to the NCI CTCAE v5 for the combination of RMC-4360 and cobimetinib or RMC-4360 and osimertinib

Recruiting

Decorative Caduceus

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Sol...

Identify nature and frequency of dose limiting toxicities

Recruiting

Share